Transition to the standard models of drug supply for patients with rare diseases
Provision of necessary medications for patients with orphan diseases is concidered. The problems of the current legislation in the subject area are stated. Conclusions are made on the need to rethink the situation of drug provision. Proposals are made to develop a State program "Dangerous Diseases of High Cost".